Compare Illumina, Inc. (ILMN) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Lowe`s Companies Inc — how do they compare? Illumina, Inc. trades at $182.09 (market cap $27.94B), while Lowe`s Companies Inc trades at $205 (market cap $114.78B). The key difference: Lowe`s Companies Inc is far larger — about 4.1× Illumina, Inc.'s market cap, and Lowe`s Companies Inc pays a 2.44% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | LOW | |
|---|---|---|
Market Cap | $27.94B | $114.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $287.39 |
52-Week Low | $91.00 | $204.76 |
Enterprise Value | $29.33B | $156.54B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Lowe's (LOW) trades at $204.08, down 2.23% on the day, amid a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.03 exceeding the $2.97 estimate. Revenue for 2025 was $83.67 billion, with a net income margin of 7.51%. The company maintains a strong dividend history, recently declaring a $1.25 per share dividend payable in August 2026.
The outlook is mixed. Strong analyst consensus, with a $260.88 price target and 60.79% buy ratings, suggests upside potential. However, high debt levels, with a debt-to-asset ratio of 82.33% for 2025, and a projected net cash flow deficit of $2.3 billion for 2026 present significant financial risks. Competitive pressures in the home improvement sector remain a key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
